Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.

Celcuity Inc.

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Celcuity today and set a price target of $94.00. Ramakanth covers the He...

H.C. Wainwright Sticks to Their Hold Rating for Celcuity (CELC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC – Research Report) and BioNTech SE (B...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CELC	$124.64	0.00%	1.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CELC	$124.64	0%	1.12M
3
4
5
6

CELC

CELC

Dividend Overview

Get Celcuity Inc. Data in Excel

Get Celcuity Inc. Data in Excel